APLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Apellis Pharmaceuticals's Gross Profit for the three months ended in Dec. 2024 was $171.7 Mil. Apellis Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $212.5 Mil. Therefore, Apellis Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2024 was 80.78%.
The historical rank and industry rank for Apellis Pharmaceuticals's Gross Margin % or its related term are showing as below:
During the past 12 years, the highest Gross Margin % of Apellis Pharmaceuticals was 92.53%. The lowest was 84.93%. And the median was 90.01%.
Apellis Pharmaceuticals had a gross margin of 80.78% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Apellis Pharmaceuticals was 0.00% per year.
The historical data trend for Apellis Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apellis Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
90.01 | 92.19 | 92.53 | 85.25 | 84.93 |
Apellis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
86.40 | 88.27 | 88.43 | 82.95 | 80.78 |
For the Biotechnology subindustry, Apellis Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Apellis Pharmaceuticals's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Apellis Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as
Gross Margin % (A: Dec. 2024 ) | = | Gross Profit (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | 663.6 | / | 781.367 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (781.367 - 117.723) | / | 781.367 | |
= | 84.93 % |
Apellis Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 171.7 | / | 212.528 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (212.528 - 40.856) | / | 212.528 | |
= | 80.78 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Apellis Pharmaceuticals (NAS:APLS) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Apellis Pharmaceuticals had a gross margin of 80.78% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
James George Chopas | officer: See Remarks | 950 WINTER STREET, WALTHAM MA 02451 |
David O. Watson | officer: General Counsel | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Mark Jeffrey Delong | officer: Senior Vice President | 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Adam J. Townsend | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Pascal Deschatelets | officer: Chief Operating Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Karen Lewis | officer: Chief People Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Jeffrey Eisele | officer: See Remarks | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Nur Nicholson | officer: Chief Technical Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Timothy Eugene Sullivan | officer: Chief Financial Officer | 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199 |
Cedric Francois | director, 10 percent owner, officer: Chief Executive Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Caroline Baumal | officer: Chief Medical Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
A. Sinclair Dunlop | director | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Lukas Scheibler | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Alec Machiels | director | 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022 |
Federico Grossi | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
From GuruFocus
By GuruFocus News • 02-25-2025
By Marketwired • 01-13-2025
By GuruFocus News • 01-27-2025
By Marketwired • 12-24-2024
By Marketwired • 11-27-2024
By GuruFocus News • 02-03-2025
By GuruFocus News • 03-01-2025
By GuruFocus News • 03-01-2025
By Marketwired • 02-20-2025
By GuruFocus News • 02-04-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.